Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients;Skuteczność i bezpieczeństwo cytalopramu i wenlafaksyny w leczeniu zaburzeń depresyjnych u chorych w podeszłym wieku

Polski Merkuriusz Lekarski

Volumn 17, Issue 102, 2004, Pages 621-624

  Gałecki, Piotr ^a,b   Florkowski, Antoni ^a   Pietras, Tadeusz ^a   Kołodziejska, Izabela ^a   Nowakowski, Tomasz ^a   Pawełczyk, Agnieszka ^a   Zboralski, Krzysztof ^a  

^a Klinika Psychiatrii I Zaburzen N   (Poland)

^b Klinika Psychiatrii I Zaburzen N   (Poland)

Author keywords

Citalopram; Depressive disorders; Elderly age; Venlafaxine

Indexed keywords

CITALOPRAM; VENLAFAXINE;

AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; GERIATRIC CARE; GERONTOPSYCHIATRY; HUMAN; MAJOR CLINICAL STUDY; TREATMENT OUTCOME;

AGED; CITALOPRAM; COGNITION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS;

EID: 11844269202     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Amore M. i wsp.: Long-term treatment of geropsychiatric depressed patients with venlafaxine. J. Affect. Disord., 1997, 46, 293-296.
2. Bech P. i wsp.: Scale for the assessment of diagnosis and severity of mental disorders. Acta Psychiatr. Scand., 1993, 87, suppl. 372.
3. Beekman A.T.F.: Anxiety and depression in later life: co-occurrence and communality of risk factors. American J. Psych., 2000, 157, 89-95.
4. Bilikiewicz A.: Depresja u ludzi w wieku podeszłym. Lȩk i Depresja, 1996, 1, 332-340.
5. Brunello N. i wsp.: The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur. Neuropsychopharm., 2002, 12, 461-475.
6. Chisholm D. i wsp.: Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br. J. Psychiatry, 2004, 184, 393-403.
7. Copeland I.R.M. i wsp.: Depression among older people in Europe: the EURODEP studies. World Psychiatry, 2003, 3, 45-49.
8. DeVane C.L. i wsp.: Pharamcokinetic considerations of antidepressant use in the elderly. J. Clin. Psychiatry, 1999, 60, suppl. 2, 38-44.
9. Folstein M.F. i wsp.: "Mini-mental State": a practical method for granding the cognitive state. J. Psychiatr. Res., 1975, 12, 189-198.
10. Goldberg R.J. i wsp.: Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drug. Aging., 1997, 11, 119-31.
11. Hamilton M.: Developmant of a rating scale for primary depressive illness. Brit. J. Social Clin. Psychol., 1967, 6, 278-296.
12. Hybels C.F. i wsp.: Epidemiology of late-life mental disorders. Clin. Geriatr. Med. 2003, 19, 663-696.
13. Kantona C. i wsp.: Antidepressants for elderly people: should selective serotonin reuptake inhibitors (SSRIs) be the first-line choice? Pirimary Care Psychiatry. 1996, 2, 123-130.
14. Kerr J.S. i wsp.: Cytalopram and other antidepressants: comparative effects on cognitive function and psychomotor performance. J. Serotonin Res., 1996, 3, 123-129.
15. Khan A. i wsp.: Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol. Bull, 1995, 31, 753-758.
16. Kirby D. i wsp.: Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients. Int. J. Geriatr. Psychiatry, 2001, 16, 484-493.
17. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Badawcze kryteria díagnostyczne. Uniw. Wyd. Med ."Vesalius", IPiN. Kraków-Warszawa, 1998.
18. Lader M. i wsp.: The effects of cytalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur. J. Clin. Pharmacol., 1986, 31, 183-190.
19. Livingston G. i wsp.: The epidemiology of psychiatric disorders in the elderly. Int. Rev. Psychiatry, 1993, 5, 317-326.
20. Nyth A.L. i wsp.: A controlled multicenter clinical study of cytalopram and placebo in elderly depressed patients with and without concomitant results. Acta Psychiatrica Scand. 1992, 86: 138-145.
21. Overo K.: Cytalopram versus amitryptyline in depressed elderly. American Psychiatric Association. 150th Annual Meeting. San Diego. Calif. USA. 1997.
22. Pużyński S.: Zaburzenia afektywne. Terapia, 2004, 4, 3-7.
23. Rochat B. i wsp.: Stereoselective biotransformation of the selective serotonin reuptake inhibitor cytalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem. Pharmacol., 1998, 56, 15-23.
24. Rzewuska M. i wsp.: Leczenie zaburzeń psychicznych. PZWL. Warszawa. 2000.
25. Sand P.G.: i wsp.: SNRI and hyponatraemia. Int. J. Geriatr. Psychiatry, 2002, 17, 491-492.
26. Sołtys K. i wsp.: Wpływ hospitalizacji na wystȩpowanie objawów depresji u osób w wieku podeszlym. Roczn. Psychoger., 1999, 1, 47-53.
27. Staab J.P. i wsp.: Efficacy of venlafaxine in geriatric depression. Depress Anxiety, 2000, 12, suppl. 1, 63-68.
28. Stordal E. i wsp.: Depression in relation to age and gender in the general population. Acta Psychiatr. Scan., 2001, 104, 210-213.
29. Turczyński J. i wsp.: Depresjia u osób w podeszłym wieku. Psychiatr. Prakt. Ogólnolek., 2002, 2, 99-107.
30. Wetterling T. i wsp.: Affective disorders in older inpatients. Int. J. Geriatr. Psychiatry, 2004, 19, 487-492.
31. Yesavage J.A.: Geriatric Depression Scale. Psychopharmacol. Bull., 1988, 24, 709-710.